Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ALMOTRIPTAN vs ALPELISIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

ALMOTRIPTAN vs ALPELISIB: Safety Overview

Metric ALMOTRIPTAN ALPELISIB
Total FAERS Reports 279 8,419
Deaths Reported 27 1,271
Death Rate 9.7% 15.1%
Hospitalizations 76 1,705
Average Patient Age 49.5 yrs 58.8 yrs
% Female Patients 42.4% 94.7%
FDA Approval Date N/A Apr 24, 2024
Manufacturer N/A Novartis Pharmaceuticals Corporation
Route N/A ORAL
Marketing Status N/A Prescription